Jake Taylor-King, Co-founder & CIO, Relation Therapeutics | Slush 2025
summary
Relation Therapeutics rebuilds a biotech around AI, claiming a ~100-person company that runs the largest multiomic bone study with 550 consented patients from 15 London hospitals and scaled single‑cell profiling into dermatology. The pipeline combines whole‑genome sequencing, LLMs on DNA to score risk, lab‑in‑the‑loop experiments to test reversibility, and Aentic systems for target contextualization; public datasets are judged insufficient so proprietary multiomic data drives target choices.
AI-written summary · about
chapters (6)
- 0:00Introduction and trends
- 1:30Drug discovery challenges
- 4:44Data gaps in target discovery
- 6:52Lab-in-the-loop approach
- 8:39AI-driven target identification
- 10:25Closing and call to action
related talks
21mShaping the future of health: Boehringer Ingelheim's Data & AI Journey
34mFrom Data to Discovery: How AI Is Finding Hidden Cures
17mNews in Drug Development & AI
20mTranslating a Trillion Pointo Diseases of Data into Therapies
21mHealthtech, day 2
04mThe Intersection of Neuroscience, AI, and Hardware: A Conversation
10mGenesis Startup Competition Pitch
10mGenesis Final Round: Nanyang Biologics